Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted March 8, 2007
FTC Files Against Maker of Calcium and Fertility Supplements
The defendants entered into the orders in 2000 to settle FTC charges that they made unsubstantiated claims about the efficacy of two products – BeneFin and SkinAnswer – in the prevention, treatment, and cure of cancer. According to the FTC, the defendants’ claims that Fertil Male improves male fertility are based on flawed scientific studies. The Commission also charged that the defendants have made numerous unsubstantiated claims about the benefits of AdvaCAL, and misrepresented test results and studies involving AdvaCAL and other calcium products. The FTC charged that the studies do not support the claims, and that the studies of AdvaCAL are “fatally flawed.”
The FTC charged that the defendants do not have competent and reliable scientific evidence to back up their claims and have misrepresented the results of scientific research when claiming:
Fertil Male improves male fertility;
AdvaCAL is more absorbable than other types of calcium;
AdvaCAL is superior to other calcium or prescription drug products at building bone or increasing bone mineral density; and
AdvaCAL is superior to other calcium products in preventing or reducing the risk of fractures. The products are sold on the Internet, in catalogs, by direct mail, on infomercials, and at retail. A one-month supply of Fertil Male costs $34.95 at retail. A 25-day supply of AdvaCAL costs $39.95 at retail.
The FTC is seeking to recover all revenues stemming from the defendants’ order violations.